# Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

> **NCT00006108** · PHASE1,PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** capecitabine
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00006108
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** 2001-09
- **Final completion:** 2002-07
- **Target enrollment:** — (—)
- **Last updated:** 2012-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006108, "Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00006108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*